Second Trimester Abortion Clinical Trial
Official title:
Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia
Verified date | July 2021 |
Source | Gynuity Health Projects |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot study seeks to evaluate the safety, acceptability and feasibility of a shortened outpatient procedure for medical abortion at 13-18 weeks gestation. It also seeks to document the roles of health workers in providing services related to later abortion care. Participants will take a single dose of 200 mg mifepristone orally, followed 24-48 hours later with 400 mcg misoprostol sublingually prior to arriving at the study clinic. Repeat doses of 400 mcg misoprostol will be administered sublingually every three hours at the clinic until the abortion is achieved. If expulsion does not occur by a certain time prior to the clinic closing that day, D&E will be performed to complete the abortion.
Status | Terminated |
Enrollment | 16 |
Est. completion date | April 3, 2021 |
Est. primary completion date | April 3, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Have an intrauterine pregnancy of 13-18 weeks gestation according to ultrasound 2. Meet legal criteria to obtain abortion 3. Be at least 18 years old 4. Have access to a phone where she can be reached for the 2-week follow up 5. Be willing to follow pilot study procedures Exclusion Criteria: 1. Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol 2. Any contraindications to vaginal delivery 3. More than one prior cesarean delivery 4. Staying more than 2 hours away from the clinic |
Country | Name | City | State |
---|---|---|---|
Colombia | Fundacion Orientame | Bogotá |
Lead Sponsor | Collaborator |
---|---|
Gynuity Health Projects |
Colombia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Successful medical abortion | Proportion of women who have a successful abortion with medication only and are discharged from care on the same day as misoprostol induction. | 0-60 hours after mifepristone | |
Secondary | Induction-to-abortion interval | Time (median min/hrs) from first misoprostol dose until fetal and placental expulsion | 0-12 hours after misoprostol | |
Secondary | Initiation-to-abortion interval | Time (median min/hrs) from mifepristone administration until fetal and placental expulsion | 0-60 hours after mifepristone | |
Secondary | Total dose of misoprostol administered | Mean number of misoprostol doses administered to achieve abortion | 0-12 hours after misoprostol | |
Secondary | Method safety | Proportion of participants who experience: extramural delivery, hemorrhage requiring transfusion, infection, uterine rupture, prolonged hospitalization, any complications | Two weeks after mifepristone | |
Secondary | Tasks performed by clinic staff | Type of task performed (i.e. counseling, monitoring vital signs, administering drugs, monitoring woman's condition, post-abortion contraception, managing discharge) per cadre of provider | From enrollment through discharge from care (approx. 3 days) | |
Secondary | Total clinic time | Time (median hrs) since arrival to clinic on day of misoprostol dosing to discharge from care that same day | 0-12 hours from arrival at clinic on day of induction with misoprostol | |
Secondary | Pain with procedure | Mean pain score (scale 0-10) | 0-12 hours after first misoprostol dose | |
Secondary | Side effects | Report of side effects and proportion of participants who experienced each one | 0-12 hours after first misoprostol dose | |
Secondary | Satisfaction with procedure | Proportion of participants who reported the procedure as satisfactory or very satisfactory | Prior to discharge from care on day of abortion, up to 12 hours after first misoprostol dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03400358 -
Uterocervical Angle in the Pregnancy Termination of Multiparous Women
|
N/A | |
Recruiting |
NCT04501809 -
Second Trimester Pregnancy Termination in Women With Previous Caesarean Sections
|
N/A | |
Recruiting |
NCT03044093 -
Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion
|
Phase 4 | |
Enrolling by invitation |
NCT06078501 -
MisOpRostol Effect on Second Trimester Abortion Blood Loss
|
Phase 3 | |
Completed |
NCT04181541 -
Midlevel Versus Physician-provided Medical Abortion in the Second Trimester
|
N/A | |
Completed |
NCT06164067 -
The Role of Cervical Consistency Index and Uterocervical Angles in Medical Termination
|
||
Completed |
NCT02033083 -
Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation
|
N/A | |
Recruiting |
NCT06123026 -
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
|
Phase 4 | |
Terminated |
NCT03714880 -
Cervical Preparation With Mifepristone Prior to Osmotic Dilators
|
Phase 2 | |
Completed |
NCT03407521 -
Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion
|
Phase 4 |